Phosphatidylcholine Supplementation in Infants

Withdrawn before enrolling · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Schizophrenia, Diminished P50 Sensory Gating

In brief

Sensory gating is defined as the automatic process of inhibiting brain response to repeated auditory sounds. Infants who brains respond similarly to two identical sounds presented about 1/2 second apart are more likely to have later problems with attention than infants who suppress response to the second sound. This study will examine whether providing a nutritional supplement, phosphatidylcholine, for two months in infancy will result in an increased likelihood of developing more robust sensory gating.

Key facts

Study ID

NCT01905605

Run by

University of Colorado, Denver

People needed

0

Starts

2013-09-01

Expected to finish

2017-01-01

Last updated by the study team

2020-09-02

Who can join

Age: 0 and older, up to 0. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy infant has an age (adjusted for gestational age at birth) of 1-7 weeks
• Diminished P50 sensory gating (ratio greater than or equal to 0.50)

You may not qualify if…

• No maternal reported tobacco use for greater than 1 year and no current tobacco use (as measured by urine cotinine levels)
• Trimethylaminuria, renal disease, liver disease, known chromosomal abnormality, chronic neurological disorder, premature birth, prenatal exposure to exogenous steroid use

Where it is running

• University of Colorado Denver — Aurora, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.